Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam Kittai

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Cancer|May 26, 2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J Gordon, Michael Churnetski, Hamood Alqahtani, et al.
Blood Advances|November 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLLJacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, et al.
Blood|August 2, 2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiationSeema A Bhat, John Gambril, Leylah Azali, et al.
Journal of Hematology & Oncology|July 14, 2022
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiationSunnia T Chen, Leylah Azali, Lindsay Rosen, et al.
Research Square|February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Cancer|May 26, 2018
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinibMax J Gordon, Michael Churnetski, Hamood Alqahtani, et al.
Blood Advances|November 19, 2024
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLLJacob D Soumerai, Jacqueline Barrientos, Inhye Ahn, et al.
Blood|August 2, 2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiationSeema A Bhat, John Gambril, Leylah Azali, et al.
Journal of Hematology & Oncology|July 14, 2022
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiationSunnia T Chen, Leylah Azali, Lindsay Rosen, et al.
Research Square|February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.
Pageof 2